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on	Days	1,	7,	and	28.	Primary	end	point:	 tacrolimus	AUC24. Secondary end points in-
cluded tacrolimus C24 and Cmax.	Endpoints	compared	between	PR-	T	and	IR-	T	on	Days	1,	
7,	and	28.	Predefined	similarity	interval	for	CIs	of	LSM	ratios:	80%-	125%.	PK	analysis	set	
comprised	33	patients	(PR-	T,	n	=	15;	IR-	T,	n	=	18).	Overall,	AUC24 and Cmax were lower on 
Day	1	vs	7	and	28.	Geometric	LSM	ratios	of	PR-	T:IR-	T	on	Days	1,	7,	and	28	were	66.3%,	
92.5%,	99.9%,	respectively,	for	AUC24; 66.3%, 82.2%, 90.9% for C24; and 77.3%, 120.3%, 
92.2% for Cmax.	AUC24 90% CI within predefined similarity interval on Day 28; other 
90%	CIs	fell	outside.	Linear	relationship	was	similar	between	AUC24 and C24, and be-
tween tacrolimus formulations, suggesting that the same therapeutic drug monitoring 
method can be used with both formulations in de novo pediatric allograft recipients.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial	License,	which	permits	use,	distribution	and	reproduction	
in	any	medium,	provided	the	original	work	is	properly	cited	and	is	not	used	for	commercial	purposes.
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1  | INTRODUC TION
Tacrolimus is the mainstay of immunosuppression regimens after 
solid organ transplantation.1	Due	to	its	narrow	therapeutic	index,	
it	 is	 essential	 that	 tacrolimus	 exposure	 is	 maintained	 within	 a	
tightly-	defined	 range,	 as	 over-	exposure	 can	 cause	 drug-	related	
toxicity	and	side	effects,2	and	under-	exposure	is	associated	with	
poor clinical efficacy outcomes.3,4 Oral bioavailability of tacroli-
mus shows large variability between patients5; therefore, the dose 




however, this is not always easy or practical for the patient and/
or treatment center. Trough tacrolimus plasma levels correlate 
with	AUC7 and, although this correlation may vary depending on 
clinical circumstances, they are widely used for monitoring tacro-
limus	exposure	following	solid	organ	transplantation	in	adult	and	
pediatric patients.7	Maintaining	adequate	exposure	to	tacrolimus	




Oral	 tacrolimus	 immediate-	release	 formulations	 for	 twice-	
daily administration are available as capsules, and granules for 
oral suspension; tacrolimus is also available as a once daily, 
prolonged-	release	 formulation.	 The	 immediate-	release	 formula-
tions	 are	 approved	 for	 the	 prophylaxis	 of	 transplant	 rejection	 in	
adult	 and	 pediatric	 patients,	while	 the	 prolonged-	release	 formu-
lation	 is	 approved	 for	 the	 prophylaxis	 of	 transplant	 rejection	 in	
adult	 kidney	and	 liver	 recipients	 in	 several	 countries.	 Limited	PK	
data	 for	 prolonged-	release	 tacrolimus	 in	 pediatric	 patients	 are	
available from small studies that have been conducted in stable 
liver	or	kidney	 transplant	patients	converted	 from	 immediate-	 to	
prolonged-	release	tacrolimus.8,9	The	PK	of	the	prolonged-	release	
formulation have been characterized in the adult de novo trans-
plant population,10-12 and no differences in interactions with other 
immunosuppressive	 therapies	 compared	 with	 immediate-	release	





and heart transplant patients.




release	 tacrolimus	 (Advagraf™,	 Astellas	 Pharma	 Europe	 BV,	
Netherlands)	 and	 immediate-	release	 tacrolimus	 (Prograf™,	 Astellas	
Pharma	Ltd,	Chertsey,	UK)	in	de	novo	pediatric	allograft	recipients.	
The study was conducted at eight sites in five countries (UK, France, 
Czech	Republic,	 Italy,	 and	Poland)	 between	February	 9,	 2012	 and	
June	23,	2016.
The study was conducted in accordance with Good Clinical 
Practice, International Council on Harmonisation guidelines, and the 
Declaration	of	Helsinki.	The	 independent	ethics	committee	and/or	
review board from each site granted approval for the study. Patients, 
or their parent/guardian, provided written informed consent to par-
ticipate, and could withdraw from the study at any time.
2.2 | Patients
De	novo	pediatric	patients	aged	<16	years,	undergoing	primary	kid-




to have gastric motility and adequate renal function before the first 
PK assessment.
Exclusion	 criteria	 were:	 multiorgan	 transplant	 or	 previous	 re-
ceipt	of	an	organ	 (including	retransplantation),	pulmonary	vascular	
resistance	 (≥4	 Wood	 units	 despite	 medication),	 renal	 impairment	
(serum	 creatinine	≥2.6	mg/dL;	 except	 for	 kidney	 recipients),	 and	
liver	 disease	 (except	 for	 liver	 recipients).	 Other	 exclusion	 criteria	
were systemic immunosuppressive medication for indications other 
than transplantation, human immunodeficiency virus, hepatitis B or 
C	virus,	and	need	for	medication	or	substances	known	to	interfere	




on	 Day	 1	 post-	transplantation	 to	 receive	 once	 daily,	 prolonged-	
release	tacrolimus,	or	twice-	daily,	immediate-	release	tacrolimus-	based	
K E Y W O R D S
heart	transplantation,	kidney	transplantation,	liver	transplantation,	pediatrics,	
pharmacokinetics,	tacrolimus
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regimens.	Prolonged-	release	tacrolimus	was	given	as	a	single	oral	daily	
dose	in	the	morning,	while	immediate-	release	tacrolimus	was	admin-
istered orally in two equal doses, in the morning and evening. If the 
patient	was	 unable	 to	 swallow	 the	 capsule	 in	 the	 immediate	 post-	
transplantation period, administration of the capsule contents as a 




heart	 transplant	 recipients,	 the	 initial	daily	dose	of	prolonged-	or	
immediate-	release	 tacrolimus	 (0.075	mg/kg)	 was	 administered	
within	4	days	of	skin	closure;	in	liver	transplant	patients,	the	dose	
(0.3	mg/kg)	was	given	within	2	days	after	skin	closure;	and	for	kid-
ney	 transplant	 recipients,	 the	 dose	 (0.3	mg/kg)	 was	 introduced	
within 24 hours following reperfusion. Subsequent tacrolimus 
doses were adjusted based on clinical evidence of efficacy, adverse 
events, and in order to achieve recommended target whole blood 
trough	levels	(Days	1-	21:	10-	20	ng/mL;	Days	22	onwards:	5-	15	ng/
mL).
Patients	 could	 receive	 concomitant	 basiliximab	 and	MMF,	 ad-
ministered as per standard clinical practice, and corticosteroids, as 






arm. PK profiles on Days 7 and 28 were performed after a minimum 
of 3 days without a dose change.
Blood	 samples	 (2	mL	 aliquots)	were	 collected	 into	 tubes	 con-
taining	ethylenediaminetetraacetic	acid	as	an	anticoagulant,	mixed,	
and	 frozen	 at	 −20°C	 within	 2	hours	 of	 collection.	 Samples	 were	
then stored until shipment to the central laboratory for bioanalysis. 
Based	 on	 the	 method	 developed	 by	Alak	 et	al,13 tacrolimus con-
centrations were measured using a validated HPLC/MS/MS assay 





using C18 200 mg/3 mL cartridges, and elutes were evaporated to 
dryness	 under	 a	 stream	 of	 nitrogen	 at	 40°C.	 Residues	were	 then	
redissolved	in	a	50:50	mix	(vol/vol)	of	acetonitrile	and	water,	mixed,	
Type of transplantation 
Study day
Corticosteroid dose








Day 1 60 mg/m2 N/A
Day 2 N/A 40 mg/m2
Day 3 N/A 30 mg/m2
Day 4 N/A 20 mg/m2





Day	−1 60 mg/m2 N/A
Day 1 N/A 40 mg/m2
Day 2 N/A 30 mg/m2
Day 3 N/A 20 mg/m2





Day	−3 60 mg/m2 N/A
Days	−2	to	7 N/A 40 mg/m2
Days 8 to 14 N/A 30 mg/m2
Days 15 to 28 N/A 20 mg/m2
TABLE  1 Corticosteroid dosing 
schedule
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and centrifuged, before being submitted for HPLC/MS/MS.14	 All	
procedures were performed in compliance with the principles of 
Good Laboratory Practice.
Routine monitoring of whole blood trough levels of tacrolimus 
during the study was carried out locally using the center’s usual 
assay	method	(such	as	HPLC/MS/MS)	or	immunoassay).
The	 primary	 end	point	 was	 estimation	 of	 tacrolimus	 AUC24 on 
Days	1,	7,	and	28	 for	prolonged-	vs	 immediate-	release	 tacrolimus.	
The	 secondary	 endpoints	 were	 estimation	 of	 maximum	 tacroli-
mus concentration (Cmax),	 time	to	Cmax (Tmax),	and	concentration	at	
24 hours (C24)	on	Days	1,	7,	and	28.
2.5 | Statistical analyses and sample size calculation
Based	 on	 previous	 experience,	 a	 sample	 size	 of	 48	 patients	 (24	
[eight	per	transplanted	organ	type]	per	treatment	arm),	with	three	
complete evaluable PK profiles, was proposed as adequate to pro-
vide	additional	evidence	of	the	PK	of	prolonged-	release	relative	to	
immediate-	release	 tacrolimus	 in	 the	 patient	 populations	 included	
in this study. If there were insufficient patients in one organ group 
within a treatment arm, more patients could be included in the 
other	organ	groups	to	compensate.	Eligible	patients	were	assigned	
a number on Day 1, and randomized centrally, using an interactive 
voice response system. The randomization sequence for allocating 
patients to treatment arms was prepared under the responsibility 
of	the	Global	Data	Science	Department	of	Astellas	Pharma	Global	
Development.
The	 PKAS	 included	 all	 randomized	 and	 transplanted	 pa-
tients who received at least one dose of study medication and 
provided	 three	 complete	PK	profiles.	Analyses	were	 performed	
on	 the	 PKAS	 overall	 and	 by	 treatment	 arm.	 Standard	 non-	
compartmental methods were used to estimate PK parameters. 
AUC24	was	calculated	using	the	linear-	log	trapezoidal	rule.	In	the	
primary	analysis,	AUC24	was	compared	between	prolonged-	and	
immediate-	release	 tacrolimus	 using	 an	 analysis	 of	 covariance	
model	 on	 the	 log-	transformed	 PK	 parameter	 with	 treatment,	
organ transplanted, and site nested within organ transplanted, 
as	 fixed	 effects,	 and	 baseline	 age	 as	 a	 continuous	 covariate.	
Separate analyses were performed for dosing Days 1, 7, and 28, 
without adjustment for multiplicity. LSM differences between 
the	treatments	(and	the	corresponding	90%	CI)	were	back	trans-
formed	 to	 the	original	 scale,	 and	 expressed	 as	 a	 percentage,	 to	
obtain an estimate for the geometric LSM ratio of the treatments 
(prolonged-	release:immediate-	release	 tacrolimus)	 with	 90%	 CI.	
The PK parameters C24 and Cmax (morning Cmax for patients re-
ceiving	 immediate-	release	 tacrolimus)	 were	 analyzed	 using	 the	
same model as for the primary analysis. The predefined similarity 
interval	for	CIs	of	LSM	ratios	was	80%-	125%.
Correlation of C24	 to	AUC24 for both treatments was assessed 
using a regression analysis and by calculating the ρ.	 All	 data	 pro-




Of 47 patients assessed for eligibility, 44 were enrolled and received 
study treatment, of whom 33 provided three complete PK profiles 
and	 comprised	 the	 PKAS.	 Fifteen	 patients	 received	 prolonged-	
release	tacrolimus	 (kidney,	n	=	10;	 liver,	n	=	3;	heart,	n	=	2),	and	18	
received	 the	 immediate-	release	 formulation	 (kidney,	 n	=	10;	 liver,	
n	=	5;	heart,	n	=	3)	(Figure	1).
The baseline demographics and characteristics were similar be-
tween	 treatment	 arms	 (Table	2).	Most	 patients	were	male	 (81.8%)	
and	 white	 (96.4%),	 and	 the	 mean	±	SD	 age	 was	 10.1	±	3.2	years	
(range	 4-	15	years).	 Overall,	 63.6%	 of	 patients	 were	 children	
(aged	 ≥2	 to	 ≤11	years)	 and	 36.4%	were	 adolescents	 (aged	 ≥12	 to	
<16	years).	 The	mean	±	SD	weight	 and	height	were	33.5	±	12.8	kg	
and	 137.5	±	20.1	cm,	 respectively,	 but	 there	 was	 wide	 variance.	
Donor characteristics were similar between arms, and most patients 
(78.8%)	had	received	organs	from	deceased	donors.
3.2 | Dosage and trough levels
The	 mean	±	SD	 tacrolimus	 daily	 doses	 with	 immediate-	release	
tacrolimus	 on	 Days	 1,	 7,	 and	 28	 were	 0.25	±	0.09,	 0.22	±	0.10,	
and	 0.20	±	0.08	mg/kg,	 respectively,	 and	 with	 prolonged-	release	
tacrolimus	 were	 0.26	±	0.08,	 0.27	±	0.11,	 and	 0.25	±	0.12	mg/kg	
(Figure	2A).	The	mean	±	SD	tacrolimus	trough	levels	with	immediate-	
release	tacrolimus	on	Days	1,	7,	and	28	were	8.3	±	4.8,	9.5	±	2.9,	and	
8.5	±	3.3	ng/mL,	 respectively,	 and	 with	 prolonged-	release	 tacroli-
mus	were	6.1	±	3.9,	8.8	±	4.1,	and	8.0	±	3.6	ng/mL.
3.3 | Tacrolimus blood concentration–time profile
The mean whole blood tacrolimus concentration–time curve for 
the	 24	hours	 after	 administration	 of	 prolonged-	release	 tacrolimus	
was	 smooth,	 due	 to	 the	 once-	daily	 dosing	 regimen.	 By	 contrast,	





In	both	treatment	arms,	mean	AUC24 was lower on Day 1 than on 
Days	 7	 and	 28	 (Figure	2B).	 Systemic	 exposure	 to	 tacrolimus	 was	
lower	on	Day	1	with	the	prolonged-	vs	the	 immediate-	release	for-
mulation,	 at	 an	 equivalent	 total	 daily	 dose	 (66.3%	AUC24 geomet-
ric	 LSM	 ratio	 for	 prolonged-	release:immediate-	release	 tacrolimus)	
(Figure	2B).	 Following	 dose	 adjustment,	 the	 geometric	 LSM	expo-
sure ratios on Days 7 and 28 were 92.5% and 99.9%, respectively. 
The	90%	CIs	 of	 the	AUC24 LSM ratio were within the predefined 
similarity	interval	on	Day	28	(80.6%,	123.8%),	but	not	on	Days	1	and	
7	(Figure	2B).
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The geometric LSM of tacrolimus C24 was lower on Days 1, 7, and 
28	with	prolonged-	release	tacrolimus	(4.3,	7.2,	and	5.8	ng/mL,	respec-
tively)	 than	with	 immediate-	release	 tacrolimus	 (6.5,	8.8,	and	6.4	ng/
mL).	The	C24	 geometric	LSM	ratio	on	Day	1	was	66.3%	 (Figure	2C),	
and increased to 82.2% and 90.9% on Days 7 and 28, respectively, 
following dose adjustment. However, the lower limit of the 90% CI 
fell outside the predefined similarity interval on all PK analysis days 
(Figure	2C).
For	both	prolonged-	and	immediate-	release	tacrolimus,	 linear	re-
lationships	between	tacrolimus	AUC24 and C24 were comparable, with 
a	strong	positive	correlation	(Figure	3).	The	Pearson	correlation	coef-
ficient	between	AUC24 and C24	was	0.83	and	0.84	for	prolonged-	and	
immediate-	release	 tacrolimus,	 respectively,	 and	 regression	 slopes	
were similar between formulations.
In both treatment arms, the observed LSM geometric Cmax was nu-
merically lower on Day 1 than on Days 7 and 28. The Cmax geometric 
LSM ratios on Days 1, 7, and 28 were 77.3%, 120.3%, and 92.2%, respec-
tively. On all days, either the lower or upper limit of the geometric LSM 
ratio	90%	CI	fell	outside	the	predefined	similarity	interval	(Figure	2D).
For	 both	 prolonged-	 and	 immediate-	release	 tacrolimus,	 mean	
Tmax numerically decreased from Day 1 to Days 7 and 28. Tmax was 
longer	with	prolonged-	vs	 immediate-	release	 tacrolimus	on	all	 days,	
with	the	largest	difference	observed	on	Day	1	(mean	±	SD	6.0	±	6.1	vs	
3.0	±	2.8	hours,	respectively)	(Table	3).
F IGURE  1 Patient flow through the study. aMore	than	one	reason	for	exclusion	can	apply	to	a	patient
Assessed for eligibility (N = 47)
Included in the PKAS (N = 18)
• Excluded from the PKASa (n = 6)
- Missing sampling time (n = 2)
- 12-hour PK sample missing 
(n = 1)
- AUC24 not available for all three 
PK profiles (n = 2)
- Change in study drug dose 
before PK sampling (n = 2)
- Receiving an excluded 
medication (n = 2)
- Protocol deviation (n = 2)
Randomized (N = 44)
• Kidney transplant (n = 25)
• Liver transplant (n = 12)
• Heart transplant (n = 7)
Excluded (N = 3)
• Not meeting inclusion 
criteria (n = 2)
• Other (n = 1)
PK analyzed (N = 18)
• Kidney transplant (n = 10)
• Liver transplant (n = 5)
• Heart transplant (n = 3)
Allocated to prolonged-release 
tacrolimus (N = 20)
• Received allocated intervention   
(n = 20)
Allocated to immediate-release 
tacrolimus (N = 24)
• Received allocated intervention   
(n = 24)
PK analyzed (N = 15)
• Kidney transplant (n = 10)
• Liver transplant (n = 3)
• Heart transplant (n = 2)
Included in the PKAS (N = 15)
• Excluded from the PKASa (n = 5)
- Missing sampling time (n = 1)
- AUC24 not available for all three 
PK profiles (n = 1)
- Change in study drug dose 
before PK sampling (n = 2)
- Receiving an excluded 
medication (n = 2)
- Protocol deviation (n = 1)








following	 dose	 adjustment,	AUC24 was similar for both formula-
tions by Day 28. These PK data are consistent with those reported 
for adult de novo transplant patients in two Phase 2 studies,10,11 
and	two	Phase	3	sub-	studies.15,16	 In	all	studies,	 the	mean	AUC24 
for	 tacrolimus	after	 the	 first	dose	was	 lower	with	prolonged-	vs	
immediate-	release	 tacrolimus;	however,	 exposure	after	 repeated	





tacrolimus (N = 15)
Immediate- release 
tacrolimus (N = 18) Total (N = 33) P valuea
Recipient characteristics
Age,	years
Mean	±	SD 10.5	±	3.1 9.8	±	3.4 10.1	±	3.2 0.551
Median 11.0 9.0 10.0
Minimum,	maximum 4.0, 15.0 4.0, 15.0 4.0, 15.0
Age	category,	n	(%)b
≥2	to	≤11	y	(children) 10	(66.7) 11	(61.1) 21	(63.6) 1.000
≥12	to	<16	y	(adolescents) 5	(33.3) 7	(38.9) 12	(36.4)
Sex,	n	(%)
Male 13	(86.7) 14	(77.8) 27	(81.8) 0.665
Female 2	(13.3) 4	(22.2) 6	(18.2)
Race,	n	(%)
White 13	(100.0) 14	(93.3) 27	(96.4) 1.000
Black/African	American 0 0 0
Asian 0 1	(6.7) 1	(3.6)
Missing 2 3 5
Baseline	weight,	kg
Mean	±	SD 35.8	±	12.3 31.5	±	13.3 33.5	±	12.8 0.341
Median 33.5 26.7 30.0
Minimum,	maximum 15.5, 59.4 15.9, 63.0 15.5, 63.0
Baseline height, cm
Mean	±	SD 141.7	±	20.9 134.0	±	19.3 137.5	±	20.1 0.283
Median 137.0 130.5 133.0
Minimum,	maximum 101.0, 187.7 107.0, 171.0 101.0, 187.7
Organ	transplant,	n	(%)
Kidney 10	(66.7) 10	(55.6) 20	(60.6) 0.887
Liver 3	(20.0) 5	(27.8) 8	(24.2)
Heart 2	(13.3) 3	(16.7) 5	(15.2)
Donor characteristics
Age,	years
Mean	±	SD 28.5	±	15.4 26.7	±	18.8 27.5	±	17.1 0.760
Median 30.0 25.0 27.0
Minimum,	maximum 6.0, 49.0 6.0, 77.0 6.0, 77.0
Type,	n	(%)
Living related 4	(26.7) 3	(16.7) 7	(21.2) –
Living	non-	related 0 0 0
Deceased 11	(73.3) 15	(83.3) 26	(78.8)
Due to rounding, percentages may not add up to 100%. aStatistical	difference	between	treatment	groups	was	evaluated	using	Fisher	exact	test	in	the	
case	of	categorical	variables	with	some	cells	with	expected	frequency	<5,	chi-	squared	test	in	the	case	of	categorical	variables	with	cells	with	expected	
frequency	of	≥5	and	two-	sample	T test in the case of continuous variables. bFor	patients	aged	≥0	to	≤27	d	or	≥28	d	to	≤23	mo,	n	=	0	for	both	treatment	
groups.
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transplant recipients also showed that trough levels of the two 
formulations	 became	 similar	 over	 time	 and	 that	 prolonged-	 and	





fit was comparable. This indicates that the same target trough levels 
with	prolonged-	and	immediate-	release	tacrolimus	will	result	in	sim-
ilar	systemic	exposure	to	tacrolimus	in	pediatric	de	novo	transplant	
patients, and that the same therapeutic drug monitoring method 
can be used. This PK profile is consistent with those seen in adult 
de	 novo	 kidney	 and	 liver	 transplant	 recipients,	 where	 there	 was	
strong	correlation	between	AUC24 and C24	with	both	prolonged-	(ρ 
0.83-	0.96	across	studies)	and	immediate-	release	tacrolimus	(ρ	0.76-	
0.94),10,11,15 and the slope of the line of best fit was similar for both 
formulations.
In this study, mean Cmax and C24 followed a similar pattern to 




plant recipients,10,11	 mean	 daily	 tacrolimus	 dose	 (mg/kg)	 was	 nu-
merically	 higher	with	 prolonged-	 vs	 immediate-	release	 tacrolimus.	
Following	dose	adjustment,	the	exposure	was	comparable	between	
the two formulations by Day 7.
Due to the nature of the study, there are several limitations. 
Patient numbers were small and, therefore, it was not possible to 
stratify the analyses by organ type. The study sample included only 
one	 patient	 of	 Asian	 ethnicity	 and	 no	 black	 or	 African	 American	
patients. Owing to variations in numerous factors between eth-
nic groups, including the prevalence of genes involved in the rapid 
metabolism of tacrolimus,19-21 ideally a more ethnically diverse 
population would have been included in the study. Trough tacroli-
mus levels during the study were, however, optimized for each indi-





limus may be an unsuitable formulation for younger children.
In	 conclusion,	 this	 is	 the	 first	 PK	 study	 of	 prolonged-	release	
tacrolimus	in	pediatric	de	novo	kidney,	liver,	and	heart	allograft	re-
cipients. There was a similar linear relationship between tacrolimus 
AUC24 and C24, with a strong positive correlation, and this relation-
ship	 was	 comparable	 between	 prolonged-	 and	 immediate-	release	
tacrolimus formulations. These results suggest that the same ther-




LSM ratio, % 66.3 92.5 99.9



































































Prolonged-release tacrolimus (n = 15)




































































































F IGURE  3 Linear	scatter	plot	of	AUC24 vs C24 of tacrolimus 
after	prolonged-	or	immediate-	release	tacrolimus	administration	
(PKAS)
Prolonged-release tacrolimus (n = 15), ρ = 0.83
AUC24 = 65.95 + 26.27*C24
Immediate-release tacrolimus (n = 18), ρ = 0.84
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